ADC plus immunotherapy for advanced HER2-negative breast cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced (stage 4) breast cancer that is HER2-negative (the cancer cells do not have too much HER2 protein).
- Your cancer has gotten worse after at least one prior treatment (like chemotherapy or hormone therapy). If your cancer is hormone receptor-positive, you must have also taken a CDK4/6 inhibitor.
- You have at least one tumor that can be measured on a CT scan or MRI.
- You do not have brain metastases that are causing symptoms and need urgent treatment, OR you have had treatment for brain metastases that are now stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1811, given by different methods, to find the best way to treat advanced HER2-positive breast cancer. It may help if you have had few treatments so far and have not had this type of drug before.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This trial tests a new drug (SHR2554) combined with standard hormone therapy for people with advanced or metastatic breast cancer. The goal is to see if the combination helps control the cancer better.
This trial tests whether adding two newer drugs to standard chemotherapy can improve outcomes for women with early-stage breast cancer that is hormone-receptor positive and has low HER2. The goal is to see if a combination of immunotherapy and targeted therapy helps shrink tumors before surgery.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.